EPO and hemolytic-uremic syndrome: As EPO can exert pro-thrombogenic effects, we consequently assessed the effects of EPO or pHBSP treatment on fibrin deposition and thrombocytes as surrogate parameters of microangiopathy to evaluate the potential of adverse treatment effects in HUS.